scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1001714932 |
P356 | DOI | 10.1007/S00408-013-9481-5 |
P698 | PubMed publication ID | 23728990 |
P50 | author | Ji Ye Jung | Q40606561 |
Moo Suk Park | Q59688292 | ||
Song Yee Kim | Q60311732 | ||
Young Sam Kim | Q61822423 | ||
Joon Chang | Q63809586 | ||
Se Kyu Kim | Q124799196 | ||
P2093 | author name string | Eun Young Kim | |
Sang Kook Lee | |||
Young Ae Kang | |||
P2860 | cites work | Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent | Q28191546 |
Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 | ||
Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene? | Q28305093 | ||
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group | Q29616063 | ||
Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex infection in mice. | Q33696833 | ||
Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy | Q33836681 | ||
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). | Q34081925 | ||
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement | Q34660076 | ||
Spread of nontuberculous mycobacteria from 1993 to 2006 in Koreans. | Q34884737 | ||
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review | Q36689393 | ||
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases | Q36727850 | ||
Tumor necrosis factor and tuberculosis | Q36821985 | ||
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks | Q37298854 | ||
Mycobacterial disease in patients with rheumatic disease | Q37335860 | ||
TNF-alpha in tuberculosis: a cytokine with a split personality | Q37411568 | ||
Diagnosis and treatment of lung infection with nontuberculous mycobacteria | Q37420341 | ||
Nontuberculous mycobacteria and the lung: from suspicion to treatment | Q37727884 | ||
Nontuberculous mycobacterial lung diseases | Q37776904 | ||
Tuberculosis and anti-TNF treatment: experience of a central London hospital | Q37802766 | ||
Nontuberculous mycobacteria infection in solid organ transplant recipients | Q37898048 | ||
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report | Q45180236 | ||
Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay | Q46703434 | ||
Changing epidemiology of nontuberculous mycobacterial lung disease in South Korea. | Q47593172 | ||
Granulomatous infectious diseases associated with tumor necrosis factor antagonists | Q47648712 | ||
BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. | Q53621736 | ||
Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers | Q57212364 | ||
Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network | Q81103797 | ||
Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country | Q81823239 | ||
Mycobacterial infections in the era of modern biologic agents | Q83541778 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | South Korea | Q884 |
P304 | page(s) | 565-571 | |
P577 | publication date | 2013-06-01 | |
P1433 | published in | Lung | Q15765075 |
P1476 | title | Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea | |
P478 | volume | 191 |
Q91604218 | A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment |
Q55491389 | Clinical outcomes of endoscopic mucosal resection for rectal neuroendocrine tumor. |
Q85965096 | Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area |
Q26748674 | Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease |
Q37231860 | Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study |
Q35787739 | Experimental Reactivation of Pulmonary Mycobacterium avium Complex Infection in a Modified Cornell-Like Murine Model. |
Q35822931 | High Latent TB Infection Rate and Associated Risk Factors in the Eastern China of Low TB Incidence |
Q59131827 | Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease |
Q54506955 | Non-tuberculous mycobacterial infections in psoriasis patients treated with biologics. |
Q38353491 | Nontuberculous mycobacteria infections in immunosuppressed hosts |
Q41549099 | Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor |
Q38611360 | Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy. |
Q35028459 | The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers. |
Q39449936 | Tuberculosis and biologics in rheumatology: India - A special situation. |
Search more.